Targeting postprandial hyperglycaemia in patients with type 2 diabetes: Nateglinide vs acarbose

被引：0
|
作者：
Holmes, D
Raccah, D
Escobar-Jimenez, F
Standl, E
机构：
[1] Novartis Pharma, Basel, Switzerland
[2] Novartis Pharma, Marseille, France
[3] Novartis Pharma, Granada, Spain
[4] Novartis Pharma, Munich, Germany
来源：
DIABETOLOGIA | 2001年 / 44卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
825
引用
收藏
页码：A215 / A215
页数：1
相关论文
共 50 条
  • [31] Attenuation of Postprandial Hypotension with Acarbose in Older Adults with Type 2 Diabetes Mellitus
    Madden, Kenneth M.
    Harris, David E.
    Meneilly, Graydon S.
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2015, 63 (07) : 1484 - 1486
  • [32] Cardiovascular Benefits of Acarbose vs Sulfonylureas in Patients With Type 2 Diabetes Treated With Metformin
    Hsu, Pai-Feng
    Sung, Shih-Hsien
    Cheng, Hao-Min
    Shin, Shyi-Jang
    Lin, Kun-Der
    Chong, Keong
    Yen, Fu-Shun
    Yu, Ben-Hui
    Huang, Chi-Ting
    Hsu, Chih-Cheng
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2018, 103 (10): : 3611 - 3619
  • [33] The role of GLP-1 in the postprandial effects of acarbose in type 2 diabetes
    Dalsgaard, Niels B.
    Gasbjerg, Laerke S.
    Hansen, Laura S.
    Hansen, Nina L.
    Stensen, Signe
    Hartmann, Bolette
    Rehfeld, Jens F.
    Holst, Jens J.
    Vilsboll, Tina
    Knop, Filip K.
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2021, 184 (03) : 383 - 394
  • [34] Acarbose Attenuates Postprandial Hypotension in Older Adults with Type 2 Diabetes Mellitus
    Harris, David E.
    Lockhart, Chris
    Meneilly, Graydon S.
    Madden, Kenneth M.
    DIABETES, 2011, 60 : A594 - A594
  • [35] Acarbose lowers serum triglyceride and postprandial chylomicron levels in type 2 diabetes
    Ogawa, S
    Takeuchi, K
    Ito, S
    DIABETES OBESITY & METABOLISM, 2004, 6 (05): : 384 - 390
  • [36] The effect of pioglitazone vs. acarbose on the lipid profile in patients with type 2 diabetes
    Scherbaum, W
    Göke, B
    DIABETES, 2001, 50 : A454 - A454
  • [37] Effect of nateglinide on the postprandial triglyceride and lipoprotein concentrations in subjects at risk for type 2 diabetes
    Johanson, E
    Axelsen, M
    Jansson, PA
    Taskinen, MR
    Smith, U
    DIABETES, 2003, 52 : A211 - A211
  • [38] A review of nateglinide in the management of patients with type 2 diabetes
    Tentolouris, Nicholas
    Voulgari, Christina
    Katsilambros, Nicholas
    VASCULAR HEALTH AND RISK MANAGEMENT, 2007, 3 (06) : 797 - 807
  • [39] Effect of nateglinide on postprandial hyperglycemia and hyperlipidemia in Japanese patients with type 2 diabetes: Assessment by meal tolerance tests
    Mori, Y
    Tajima, N
    DIABETES, 2004, 53 : A138 - A138
  • [40] Efficacy and safety of repaglinide vs nateglinide for treatment of Japanese patients with type 2 diabetes mellitus
    Kawamori, Ryuzo
    Kaku, Kohei
    Hanafusa, Toshiaki
    Kashiwabara, Daisuke
    Kageyama, Shigeru
    Hotta, Nigishi
    JOURNAL OF DIABETES INVESTIGATION, 2012, 3 (03) : 302 - 308
12345